前列腺癌治疗的并发症：未解决的问题。
Complications of Prostate Cancer Treatment: Open Issues.
作者信息
Angulo Javier C
机构信息
Clinical Department, Faculty of Biomedical Science, Universidad Europea, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.
Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.
出版信息
J Clin Med. 2024 May 24;13(11):3090. doi: 10.3390/jcm13113090.
Abstract
Unfortunately, prostate cancer treatment is not free of complications [...].
摘要
不幸的是，前列腺癌治疗并非没有并发症[...]。
相似文献
1
Complications of Prostate Cancer Treatment: Open Issues.前列腺癌治疗的并发症：未解决的问题。
J Clin Med. 2024 May 24;13(11):3090. doi: 10.3390/jcm13113090.
2
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.使用AR-V7生物标志物确定转移性去势抵抗性前列腺癌的治疗方案，一项可行性随机对照试验，VARIANT试验的结论
NIHR Open Res. 2023 Jan 10;2:49. doi: 10.3310/nihropenres.13284.2. eCollection 2022.
3
Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.腹腔镜及机器人辅助与开放根治性前列腺切除术治疗局限性前列腺癌的比较
Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD009625. doi: 10.1002/14651858.CD009625.pub2.
4
Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.前列腺癌根治性前列腺切除术或放疗后除尿失禁或勃起功能障碍以外的并发症发生率：一项基于人群的队列研究。
Lancet Oncol. 2014 Feb;15(2):223-31. doi: 10.1016/S1470-2045(13)70606-5. Epub 2014 Jan 17.
5
Cardiovascular Complications of Prostate Cancer Treatment.前列腺癌治疗的心血管并发症
Front Pharmacol. 2020 Dec 22;11:555475. doi: 10.3389/fphar.2020.555475. eCollection 2020.
6
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
7
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.晚期前列腺癌治疗中早期与延迟雄激素抑制疗法的比较
Cochrane Database Syst Rev. 2002(1):CD003506. doi: 10.1002/14651858.CD003506.
8
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者（AFFINITY）：一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
9
A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy.超声引导下前列腺近距离放射治疗与开放性前列腺近距离放射治疗并发症的比较。
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):909-13. doi: 10.1016/s0360-3016(00)00506-x.
10
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.人腺激肽释放酶与游离前列腺特异性抗原（PSA）的联合检测可提高总PSA中度升高患者前列腺癌与良性前列腺增生之间的鉴别能力。
Clin Chem. 1999 Nov;45(11):1960-6.
本文引用的文献
1
The effectiveness of adjustable trans-obturator male system (ATOMS) in radiated patients is reduced: A propensity score-matched analysis.可调节经闭孔男性系统（ATOMS）在放疗患者中的有效性降低：一项倾向评分匹配分析。
BJUI Compass. 2024 Feb 11;5(4):506-514. doi: 10.1002/bco2.329. eCollection 2024 Apr.
2
Results at 1 Year from SATURN, A European, Prospective, Multicenter Registry for Male Stress Urinary Incontinence Surgery.SATURN 研究：欧洲前瞻性多中心男性压力性尿失禁手术注册登记研究 1 年结果。
Eur Urol Focus. 2024 Sep;10(5):818-825. doi: 10.1016/j.euf.2024.04.003. Epub 2024 Apr 15.
3
Artificial Urinary Sphincter Complications: A Narrative Review.人工尿道括约肌并发症：叙述性综述
J Clin Med. 2024 Mar 26;13(7):1913. doi: 10.3390/jcm13071913.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
5
Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic Stenosis.前列腺切除术后、放疗后吻合口狭窄患者行背侧覆盖颊黏膜移植尿道成形术的多机构研究结果
J Urol. 2024 Apr;211(4):596-604. doi: 10.1097/JU.0000000000003848. Epub 2024 Jan 26.
6
The association of body mass index with tumor aggression among men undergoing radical prostatectomy.
Urol Oncol. 2024 Apr;42(4):116.e1-116.e7. doi: 10.1016/j.urolonc.2023.12.013. Epub 2024 Jan 22.
7
Comparison Study between Artificial Urinary Sphincter and Adjustable Male Sling: A Propensity-Score-Matched Analysis.人工尿道括约肌与可调节男性吊带的比较研究：倾向评分匹配分析
J Clin Med. 2023 Aug 24;12(17):5489. doi: 10.3390/jcm12175489.
8
Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy.前列腺切除术后辅助/挽救性放疗时患者报告的尿失禁的预测因素：手术与放疗间隔时间的影响
Cancers (Basel). 2021 Jun 29;13(13):3243. doi: 10.3390/cancers13133243.
9
Artificial urinary sphincter or a second adjustable transobturator male system offer equivalent outcomes in patients whom required revision on the initial ATOMS device: An international multi-institutional experience.人工尿括约肌或第二代可调节经肛男性系统在需要对初始 ATOMS 装置进行翻修的患者中提供等效结果：一项国际多机构经验。
Neurourol Urodyn. 2021 Mar;40(3):897-909. doi: 10.1002/nau.24646. Epub 2021 Mar 1.
10
Outcomes of a Series of Patients with Post-Prostatectomy Incontinence Treated with an Adjustable Transobturator Male System or Artificial Urinary Sphincter.一系列采用可调式经肛男性吊带系统或人工尿道括约肌治疗前列腺切除术后尿失禁患者的结局。
Adv Ther. 2021 Jan;38(1):678-690. doi: 10.1007/s12325-020-01563-z. Epub 2020 Nov 23.
Zotero 插件